CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023
Yahoo! Finance
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with significant unmet need, today announced it will make three presentations at the European Association for the Study of the Liver (EASL)'s The International Liver Congressā¢ 2023. Featured results include novel aspects of the anti-pruritic and anti-fibrotic mechanisms of seladelpar, a first-in-class oral, selective PPARĪ“ agonist, or "delpar,
Continue Reading